Fundsmith LLP Decreases Stake in Medpace Holdings, Inc. $MEDP

Fundsmith LLP lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 16.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 52,372 shares of the company’s stock after selling 10,296 shares during the period. Medpace makes up about 0.2% of Fundsmith LLP’s investment portfolio, making the stock its 26th largest position. Fundsmith LLP owned about 0.19% of Medpace worth $27,736,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Johnson Financial Group Inc. purchased a new position in shares of Medpace during the 2nd quarter worth about $27,000. Geneos Wealth Management Inc. boosted its position in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the period. Elyxium Wealth LLC bought a new position in shares of Medpace during the fourth quarter valued at approximately $30,000. Jones Financial Companies Lllp purchased a new stake in shares of Medpace in the second quarter worth approximately $30,000. Finally, Allied Private Wealth LLC bought a new stake in shares of Medpace during the 2nd quarter worth approximately $31,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on the company. Robert W. Baird raised their price objective on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. Mizuho increased their target price on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Truist Financial upped their price target on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Finally, BMO Capital Markets upped their target price on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $584.18.

Insider Activity at Medpace

In other news, Director Fred B. Davenport, Jr. sold 7,283 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total value of $4,414,590.45. Following the sale, the director directly owned 3,798 shares in the company, valued at approximately $2,302,157.70. This trade represents a 65.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brian T. Carley sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the sale, the director directly owned 27,825 shares in the company, valued at approximately $16,935,129.75. This trade represents a 15.23% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 133,821 shares of company stock worth $81,748,135. 20.50% of the stock is owned by corporate insiders.

Medpace Stock Performance

Shares of MEDP stock opened at $600.65 on Monday. The company has a market capitalization of $16.76 billion, a P/E ratio of 35.21, a P/E/G ratio of 2.68 and a beta of 1.15. The business’s 50 day moving average is $565.33 and its two-hundred day moving average is $494.30. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.